Medtronic (MDT) Asset Writedowns and Impairment (2014 - 2026)

Medtronic (MDT) has 13 years of Asset Writedowns and Impairment data on file, last reported at -$102.0 million in Q2 2026.

• For the quarter ending Q2 2026, Asset Writedowns and Impairment fell 6.25% year-over-year to -$102.0 million; the trailing twelve-month figure through Jan 2026 stood at $6.0 million (down 98.52% YoY), and the FY2024 full-year result was $371.0 million, changed N/A from the prior year.
• Asset Writedowns and Impairment declined to -$102.0 million in Q2 2026, from $36.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $466.0 million in Q2 2022 to a low of -$466.0 million in Q1 2022.
• A 5-year average of $20.6 million and a median of $23.0 million in 2023 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment surged 672.22% in 2024 and tumbled 131.07% in 2025, its largest moves.
• Tracing MDT's Asset Writedowns and Impairment over 5 years: stood at $26.0 million in 2022, then tumbled by 38.46% to $16.0 million in 2023, then jumped by 68.75% to $27.0 million in 2024, then jumped by 40.74% to $38.0 million in 2025, then sank by 368.42% to -$102.0 million in 2026.
• Business Quant data shows MDT's Asset Writedowns and Impairment at -$102.0 million in Q2 2026, $36.0 million in Q1 2026, and $38.0 million in Q4 2025.